Results 121 to 130 of about 6,131 (232)

One Single Session to Sleep Them All? The Potential of Single‐Session Interventions for Insomnia

Journal of Sleep Research, Volume 35, Issue 2, April 2026.
ABSTRACT Poor sleep and insomnia are pervasive public health concerns, with insomnia ranking as the second most prevalent mental health disorder in the general population. Moreover, insomnia is a significant predictor of subsequent depression and is frequently co‐occurring with other psychological difficulties.
Matteo Carpi, Erica Marie Szkody, Daniel Ruivo Marques   +2 more
wiley   +1 more source

The Effects of Daridorexant on Patients With Comorbid Insomnia Disorder and Untreated Mild Obstructive Sleep Apnoea: A Post Hoc Subgroup Analysis of a Phase 3, Randomised Clinical Trial

Journal of Sleep Research, Volume 35, Issue 2, April 2026.
ABSTRACT Daridorexant, a dual orexin receptor antagonist, is approved for the treatment of insomnia disorder in adults. Approximately 30%–35% of patients with insomnia disorder also have obstructive sleep apnoea (OSA) of any severity. It is unclear whether sleep medications provide safe and effective treatment for insomnia in these patients.
Christopher J. Lettieri, Orestis Briasoulis, Damien Léger, Pierre‐Philippe Luyet, Jean‐Louis Pépin, Stuart F. Quan, Janna Raphelson, Paul Saskin, Atul Malhotra   +8 more
wiley   +1 more source

Management of Insomnia Complaints by Non‐Sleep Specialist Physicians: A French DELPHI Consensus

Journal of Sleep Research, Volume 35, Issue 2, April 2026.
ABSTRACT Insomnia is the most prevalent sleep disorder and a major public health concern, affecting chronically up to 19% of the adult population in France. Despite its significant impact on quality of life, mental health, and cardiometabolic disease, insomnia disorder remains underdiagnosed and inadequately managed.
Pierre‐Alexis Geoffroy, Jean‐Louis Pépin, Marjorie Guillet, Jean‐Bastien Micoulaud‐Franchi, Yves Dauvilliers, Damien Léger, Sylvie Royant‐Parola   +6 more
wiley   +1 more source

Age at Onset and Delays in Diagnosis of Central Disorders of Hypersomnolence Over the Past 30 Years

Journal of Sleep Research, Volume 35, Issue 2, April 2026.
ABSTRACT Patients with narcolepsy type 1 (NT1), type 2 (NT2), idiopathic hypersomnia (IH) usually suffer from symptoms for years, even decades, before being diagnosed. We aimed to assess age at onset, age at diagnosis and changes in the diagnostic delays of these patients from 1990 to 2020 in a single centre.
Zhongxing Zhang, Lucie Barateau, Séverine Béziat, Ramin Khatami, Yves Dauvilliers   +4 more
wiley   +1 more source

The Number of Newly Dispensed Hypnotic Drugs During the First COVID‐19 Lockdown Period in The Netherlands

Journal of Sleep Research, Volume 35, Issue 2, April 2026.
ABSTRACT The 2019 coronavirus (COVID‐19) pandemic and associated lockdowns significantly disrupted healthcare systems, including access to pharmacological treatments such as sleep medication. This study investigated the number of first‐time dispensed hypnotic drugs during the first COVID‐19 lockdown in the Netherlands, using data from the Dutch ...
Dana M. Dijkgraaf, Pantea Kiani, Maureen N. Zijlstra, Pauline A. Hendriksen, Johan Garssen, Joris C. Verster   +5 more
wiley   +1 more source

Longitudinal association between sleep and Alzheimer's pathology

Alzheimer's &Dementia, Volume 22, Issue 3, March 2026.
Abstract INTRODUCTION Since sleep disturbance is a modifiable risk factor for Alzheimer's disease (AD), we tested associations between sleep and AD pathology in cognitively unimpaired (CU) persons. METHODS We included 223 participants from the PREVENT‐AD cohort with self‐reported measures of sleep, objective actigraphy measures of sleep, and positron ...
Bery Mohammediyan, Andrée‐Ann Baril, Alfonso Fajardo Valdez, Frédéric St‐Onge, Alexa Pichet Binette, Julie Carrier, Maiya R. Geddes, Simon Ducharme, Maxime Montembeault, Jean‐Paul Soucy, John Breitner, Judes Poirier, Sylvia Villeneuve, for the PREVENT‐AD Research Group   +13 more
wiley   +1 more source

The neuromodulatory fragility hypothesis of Alzheimer's disease pathogenesis

Alzheimer's &Dementia, Volume 22, Issue 3, March 2026.
Abstract Sporadic Alzheimer's disease (AD) is associated with numerous risk factors, yet its precise cause remains unclear. Here, we describe a novel framework for AD pathogenesis, whereby diverse risk factors converge on neuromodulatory subcortical systems to confer AD risk or resilience.
Alfie Wearn, Kate M. Onuska, Taylor W. Schmitz, Gary R. Turner, R. Nathan Spreng   +4 more
wiley   +1 more source

Sleep, Energy and Depression

Dialogues in Clinical Neuroscience & Mental Health
Sleep is a universal biological behavior that to this day remains unclear. There is a lack of consensus concerning sleep’s underlying function, making it a controversial matter. Throughout the years, many theories have been formulated with the purpose to
Erietta Karaviti
doaj   +1 more source

Orexin/Hypocretin Signaling

, 2016
Orexin/hypocretin peptide (orexin-A and orexin-B) signaling is believed to take place via the two G-protein-coupled receptors (GPCRs), named OX1 and OX2 orexin receptors, as described in the previous chapters. Signaling of orexin peptides has been investigated in diverse endogenously orexin receptor-expressing cells - mainly neurons but also other ...
openaire   +2 more sources

Molecular Determinants of Orexin Receptor Ligand Interaction : Studies on Ligand Selectivity and Impact of Calcium [PDF]

, 2014
Neuropeptides orexin-A and orexin-B, and their receptors OX1 and OX2 were first found as regulators of appetite, and later several other functions have been found as well.
Putula, Jaana
core